Status: Recruiting
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).
Participants needed: 50
Trial details
Phase: Phase 2, Phase 3Age: 1-75Biological sex: AllType: InterventionalSponsor: Hospital Israelita Albert EinsteinUpdated: Feb 1, 2019Locations: 1
Eligibility criteria
Men and Women of Any Age [+3]
Acute leukemias not in complete response (that is > 5% blast in the bone marrow) [+6]